PRKDC and colorectal carcinoma: Potential druggable targets and corresponding inhibitors were screened for CRC patients who are defined as high-DDRscore with the constructed prognostic model, and two most promising compounds, namely KU-55933 (ATM inhibitor) and NU7441 (DNA-PK inhibitor), were identified from the GDSC drug response database.